Metabolomics and Their Ability to Distinguish Thyroid Disorders: A Retrospective Pilot Study

Abstract

Early diagnosis of thyroid disorders is key to further treatment. We assessed the ability of a high-throughput proton NMR metabolomic profile to distinguish disease type amongst of Graves’ disease (n=87), Hashimoto’s thyroiditis (n=17), toxic goiter (n=11), and autoimmune thyroiditis [i. e., subacute thyroiditis (n=4), postpartum thyroiditis (n=1)]. This observational study was conducted investigating patients presenting with a thyroid disorder at a Swiss hospital endocrine referral center and an associated endocrine outpatient clinic. The main outcome was diagnosis of thyroid disorder based on classical parameters. Blood draws took place as close as possible to treatment initiation. We performed one-way ANOVA and partial least squares discriminant analysis (PLS-DA) as multivariate classification and feature ranking method. One-way ANOVA analysis yielded following significantly different metabolites, triglycerides in small VLDL, triglycerides in very small VLDL, and triglycerides in large LDL (FDR=0.04). There was no distinct separation of any of the 4 diagnoses by PLS-DA. We did not find a metabolomic biomarker combination capable of predicting diagnosis. Preanalytical issues might have influenced our results. We strongly suggest replicating our work in another cohort.

Key words

metabolomics - Graves’ disease - Hashimoto’s disease - diagnosis

• References

• 1 De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388: 906-918
• 2 Kornelius E, Yang YS, Huang CN. et al. The trends of hyperthyroidism treatment in taiwan: a nationwide population-based study. Endocr Pract 2018; 24: 573-579
• 3 Antonelli A, Ferrari SM, Corrado A. et al. Autoimmune thyroid disorders. Autoimmun Rev 2015; 14: 174-180
• 4 Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379: 1155-1166
• 5 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421
• 6 Alexander EK, Pearce EN, Brent GA. et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27: 315-389
• 7 Kang J, Zhu L, Lu J. et al. Application of metabolomics in autoimmune diseases: Insight into biomarkers and pathology. J Neuroimmunol 2015; 279: 25-32
• 8 Al-Majdoub M. Lantz Spegel P. Treatment of swedish patients with graves' hyperthyroidism is associated with changes in acylcarnitine levels. Thyroid 2017; 27: 1109-1117
• 9 Chng CL, Lim AY, Tan HC. et al. Physiological and metabolic changes during the transition from hyperthyroidism to euthyroidism in graves' disease. Thyroid 2016; 26: 1422-1430
• 10 Piras C, Arisci N, Poddighe S. et al. Metabolomic profile in hyperthyroid patients before and after antithyroid drug treatment: Correlation with thyroid hormone and TSH concentration. Int J Biochem Cell Biol 2017; 93: 119-128
• 11 Wojtowicz W, Zabek A, Deja S. et al. Serum and urine (1)H NMR-based metabolomics in the diagnosis of selected thyroid diseases. Sci Rep 2017; 7: 9108
• 12 Garber JR, Cobin RH, Gharib H. et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012; 22: 1200-1235
• 13 Soininen P, Kangas AJ, Wurtz P. et al. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 2015; 8: 192-206
• 14 Soininen P, Kangas AJ, Wurtz P. et al. High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009; 134: 1781-1785
• 15 Wang Q, Wurtz P, Auro K. et al. Metabolic profiling of pregnancy: Cross-sectional and longitudinal evidence. BMC Med 2016; 14: 205
• 16 Puska P, Stahl T. Health in all policies-the Finnish initiative: Background, principles, and current issues. Annu Rev Public Health 2010; 31: 315-328. 3 p following 328
• 17 Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformat 2016; 55: 14 10 1-14 10 91
• 18 Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Royal Statist Soc Ser B (Methodological) 1995; 57: 289-300
• 19 Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 2011; 6: 743-760
• 20 Struja T, Eckart A, Kutz A. et al. Metabolomics for prediction of relapse in graves’ disease: observational pilot study. Front Endocrinol (Lausanne) 2018; 9: 623
• 21 Wu S, Gao Y, Dong X. et al. Serum metabonomics coupled with Ingenuity Pathway Analysis characterizes metabolic perturbations in response to hypothyroidism induced by propylthiouracil in rats. J Pharm Biomed Anal 2013; 72: 109-114
• 22 Wu S, Tan G, Dong X. et al. Metabolic profiling provides a system understanding of hypothyroidism in rats and its application. PLoS One 2013; 8: e55599
• 23 Yin P, Peter A, Franken H. et al. Preanalytical aspects and sample quality assessment in metabolomics studies of human blood. Clin Chem 2013; 59: 833-845
• 24 Zivkovic AM, Wiest MM, Nguyen UT. et al. Effects of sample handling and storage on quantitative lipid analysis in human serum. Metabolomics 2009; 5: 507-516
• 25 Torell F, Bennett K, Rannar S. et al. The effects of thawing on the plasma metabolome: Evaluating differences between thawed plasma and multi-organ samples. Metabolomics 2017; 13: 66
• 26 Jobard E, Tredan O, Postoly D. et al. A systematic evaluation of blood serum and plasma pre-analytics for metabolomics cohort studies. Int J Mol Sci 2016; 17 pii E2035